AGEN - Agenus Inc logo

Agenus Inc

AGEN

Agenus Inc develops immunotherapies targeting cancer and infectious diseases, offering platforms for human monoclonal antibodies and vaccine adjuvants. Key products include the Balstilimab antibody and various checkpoint modulators in clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2000 $ USD
$1,000 invested 20 years ago โ†’$51today

Score Overview

1 Year
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growth16.20%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.8
Net Growth484.57%
Net Trend33%
Net Income Consistencyโ€”
Rev Growth-55.12%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth172.45%
Net Trend50%
Net Income Consistency
Rev Growth487.84%
Rev Trend60%
Revenue Consistency
20 Years
Score4.4
Net Growth277.35%
Net Trend44%
Net Income Consistency
Rev Growth191x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth296.90%
Net Trend46%
Net Income Consistency
Rev Growth299x
Rev Trend58%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Agenus Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • AGEN

2011: 78.6% ยท 2021: 88.9% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 9.43โ€”
1 Year2025-09-26
$ 3.95138.73%
5 Years2021-09-28
$ 102.45-90.80%
10 Years2016-09-28
$ 139.54-93.24%
20 Years2006-09-28
$ 183.70-94.87%
All Time2000-02-04
$ 7.23K-99.87%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 132M$ 92M$ 18M
2025$ 114M$ 2M
2024$ 103M-$ 227M$ 40M
2023$ 156M-$ 245M$ 76M
2022$ 98M-$ 220M$ 193M
2021$ 295M-$ 23M$ 306M
2020$ 88M-$ 180M$ 99M
2019$ 150M-$ 107M$ 61M
2018$ 36M-$ 159M$ 53M
2017$ 42M-$ 120M$ 60M
2016$ 22M-$ 126M$ 76M
2015$ 24M-$ 87M$ 171M
2014$ 6M-$ 42M$ 40M
2013$ 3M-$ 30M$ 27M
2012$ 15M-$ 11M$ 21M
2011$ 2M-$ 23M$ 10M
2010$ 3M-$ 21M$ 19M
2009$ 3M-$ 30M$ 30M
2008$ 2M-$ 28M$ 34M
2007$ 5M-$ 36M$ 18M
2006$ 692.13K-$ 51M$ 40M
2005$ 629.98K-$ 74M$ 61M
2004$ 707.07K-$ 56M$ 86M
2003$ 4M-$ 65M$ 89M
2002$ 3M-$ 55M$ 58M
2001$ 4M-$ 73M$ 60M
IPO2000$ 442.63K-$ 46M$ 99M
AGEN - Agenus Inc logo

Agenus Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 88M to $ 114M. Revenue increased in 3 of those 5 years; net income in 2.

Across Agenus Inc's full reported history, from 2000 to 2025, revenue grew from $ 442.63K to $ 114M. Revenue increased in 58% of the years measured; net income in 46%.

Agenus Inc currently holds a 20-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.

Membership

Continue AGENโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies